PDCD1 and cancer: Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) are the first two anti–PD-1 mAbs that have received US Food and Drug Administration (FDA) approval in several cancers with some overlapping indications e.g., melanoma and non-small cell lung cancer.